In a patient with systemic lupus erythematosus taking mycophenolate mofetil, hydroxychloroquine, and prednisone who has noticed skin darkening, is this a common side effect?

Skin Darkening in SLE Patients on Hydroxychloroquine

Yes, skin darkening is a recognized and relatively common side effect of hydroxychloroquine, occurring in approximately 4-15% of patients with prolonged use, and is not typically caused by mycophenolate or prednisone. 1

Understanding the Cause

The skin darkening you're observing is most likely hydroxychloroquine-induced hyperpigmentation, which presents as:

• Blue-gray or brown discoloration, typically appearing after several years of treatment (median 6.1 years, though can occur as early as 3 months) 2
• Common locations: Face (especially temples), shins, forearms, upper back, shoulders, and areas prone to sun exposure 3, 2, 4
• Pattern: Often mottled, reticulated (net-like), or diffuse 4
• May include nail pigmentation (melanonychia) 3

Mechanism

The pigmentation occurs through two primary pathways:

1. Direct melanin binding: Hydroxychloroquine binds to melanin in the skin, causing persistent pigment deposition 4
2. Post-ecchymotic pigmentation: In 92% of cases, patients report that pigmented areas were preceded by bruising or ecchymotic areas that evolved into persistent discoloration 2

Risk Factors to Assess

Independent risk factors for hydroxychloroquine-induced pigmentation include:

• Higher blood hydroxychloroquine concentrations 2
• Concurrent anticoagulant or antiplatelet therapy (aspirin, warfarin, etc.) 2
• Duration of therapy (risk increases with years of use) 1, 5
• Dosing above 5 mg/kg actual body weight 5

What to Do

Immediate Assessment

1. Verify hydroxychloroquine dosing: Ensure dose is ≤5 mg/kg actual body weight 1, 5
2. Review medication list: Check for anticoagulants/antiplatelets that increase bruising risk 2
3. Document pattern: Note if preceded by bruising or trauma 2
4. Consider skin biopsy if diagnosis uncertain: Will show pigment incontinence and iron deposition in dermis 3, 2

Management Decision Algorithm

If pigmentation is mild and asymptomatic:

• Continue hydroxychloroquine - the drug's benefits for SLE (reduced flares, organ damage, cardiovascular events, and mortality) typically outweigh cosmetic concerns 1
• Reassure patient this is a known, benign side effect
• Optimize dosing to ≤5 mg/kg if not already done 5

If pigmentation is extensive or distressing to patient:

• Reduce hydroxychloroquine dose (though no precise reduction guidelines exist) 5
• Consider switching to quinacrine for cutaneous manifestations if retinal toxicity is also a concern 6
• Do not discontinue hydroxychloroquine without careful consideration - stopping increases SLE flare risk significantly (HR 2.50) 1

If considering drug discontinuation:

• Weigh against increased risk of: SLE flares, progressive kidney damage, cardiovascular events, thrombosis (if antiphospholipid antibodies present), and mortality 1
• Discuss alternative immunosuppression if hydroxychloroquine must be stopped

Important Caveats

Mycophenolate mofetil can cause skin rashes and drug-induced dermatitis, but not typically hyperpigmentation 7, 8. If the rash is erythematous, pruritic, or associated with fever/systemic symptoms, consider mycophenolate as the culprit instead.

Prednisone does not cause hyperpigmentation and is not the source of this patient's skin darkening.

The pigmentation from hydroxychloroquine is generally irreversible or very slow to resolve even after drug discontinuation, though some gradual fading may occur over months to years 2.

Do not confuse this with lupus-related skin manifestations - hydroxychloroquine-induced pigmentation has distinct clinical and histologic features (dermal pigment deposition, iron on biopsy) versus discoid lupus lesions 3, 2.